Clustering of multiple risk factors such as impaired glucose metabolism, lipid disorders and hypertension has been shown to be the major background of atherosclerotic diseases, and disease entities such as the metabolic syndrome represent a highly atherogenic state. Although these common risks may generally co-exist by accident in one individual, clustering of multiple risk factors in the metabolic syndrome does not occur by accident, and there should be a key player for the syndrome. In 1983, we reported the method for fat analysis using computed tomography scan, which enables us to analyze intra-abdominal visceral adiposity as well as subcutaneous fat. Visceral fat accumulation has been shown to cause impaired glucose metabolism, lipid disorders, and hypertension, and therefore it is considered to be a key player in the metabolic syndrome. To clarify the mechanism by which visceral fat accumulation causes a variety of metabolic and vascular diseases, we studied the molecular characteristics of adipose tissue and adipocytes by investigating expressed genes in visceral and subcutaneous adipocytes and revealed that adipocytes, especially visceral adipocytes, secrete a variety of bioactive substances, the so-called adipocytokines. We showed that visceral fat accumulation causes abnormalities in adipocytokine secretion, such as hypersecretion of plasminogen activator inhibitor 1, which is related to thrombogenic vascular diseases. More importantly, we discovered an important benign adipocytokine named adiponectin, which protects against the development of diabetes mellitus, hypertension, inflammation, and atherosclerotic vascular diseases. Plasma levels of adiponectin decreased in individuals with visceral fat accumulation, and hypoadiponectinemia caused by visceral fat accumulation might be one of the major causes of metabolic syndrome.
Introduction
As recently as 30 years ago, individuals with massive obesity were very rare in Japan and had few metabolic and cardiovascular complications, yet I noticed that mildly obese individuals who gained 2-3 kg sometimes suffered marked metabolic and circulatory disorders. This fact suggests that the extent of body fat accumulation is not necessarily a determinant for morbidity of obesity.
Professor Vague was a pioneer of this concept. He said 60 years ago that although women normally have twice the fat levels as men, they live longer, with less morbidity from the metabolic complications of obesity. He proposed classifying android-type excess weight as high-risk obesity and gynoid type as low-risk obesity.
1 Figure 1 shows two classical paintings that suggest the important role of obesity in morbidity. The obese woman in the left panel must be ill, because this picture was taken from an illustrated book titled 'Yamai-Zoshi' (which means 'Disease Scrolls') published 800 years ago in Japan. The difference in fat topology between this woman and the girl painted by Renoir shown in the right panel is remarkable.
In the early 1980s, Professor Björntorp 2 proposed classifying obesity into central obesity and peripheral obesity, and Professor Kissebah 3 proposed the concept of upper-and lowerbody obesity, based on the waist-hip ratio, with upper-body obesity having a higher occurrence of obesity-related diseases. Current perspective favors another viewpoint. Our group reported a method for fat analysis using computed tomography (CT) scan in 1983, 4 and then proposed classifying obesity into visceral fat obesity and subcutaneous fat obesity. 5 In 1990, the International Symposium on Regional Fat Distribution and Morbidity was held in Osaka as a Satellite Symposium of the 6th International Congress on Obesity held in Kobe, Japan. This symposium, in which Professors Tarui, Bouchard, Kissebah and Björntorp served as Chairs and myself as Secretary General, may have been the first consensus meeting on the importance of intra-abdominal visceral fat with respect to obesity-related diseases.
In this review, I would like to introduce the history of the concept of visceral fat syndrome and also discuss the mechanisms of a variety of cardiometabolic complications caused by visceral fat accumulation. Figure 2 shows the first report of the method for the analysis of regional fat volume using CT scan published in 1983. 4 In this method, a human body is divided into 11 cylindrical shapes, and 11 computed tomographic sections are scanned at the middle of each segment to obtain the area of fat tissue. The volume of each cylindrical segment is calculated by multiplying a cross-sectional area of fat tissue by the height of each part. We had originally determined fat volume by the integration of CT area of multi-cut scans for abdominal subcutaneous fat and visceral fat, but multiplication of single-cut CT area at the umbilicus level by the length of abdomen turned out to be closely correlated to the volume gained by integrated multi-cut area as the gold standard. Finally, the fat area of a single CT scan at the umbiliculus level has been used as the indicator for determining subcutaneous and visceral adiposity in the abdomen. From the analysis of abdominal adipose tissue, we noticed a remarkable variation in fat distribution between the subcutaneous and intra-abdominal cavities as shown in Figure 3 . Individuals with increased visceral adiposity were shown to have more obesity-related complications by subsequent studies. Fat areas from CT images had been determined by a very primitive manual identification in the beginning, but currently are developed with very sophisticated software named 'Fat Scan,' which can detect areas with adipose tissue immediately ( Figure 4 ). 4 Using this method, we reported that visceral fat accumulation closely correlated to the impairment of glucose and lipid metabolism in 1987 6 and to hypertension in 1990. 7 Professor Despres 8 also measured intra-abdominal adiposity by CT scan and found that an increase in visceral fat caused the abnormalities in glucose and lipoprotein metabolism. Since then, many clinical studies on the correlation between visceral adiposity and disease have been performed all over the world. Figure 5 shows our group's findings on the relationship of visceral fat accumulation with the development of many common diseases. It is especially significant that visceral fat accumulation directly correlates to the development of cardiovascular disease. 9 Visceral fat accumulation is sometimes seen not only in obese individuals but also in non-obese individuals. Subjects with a visceral fat area more than 100 cm 2 have been shown to have more obesity-related diseases than obese individuals without visceral fat accumulation. 10 From these clinical studies, we proposed a disease entity named 'visceral fat syndrome,' which is similar to the syndrome X proposed by Professor Reaven 11 and the deadly quartet proposed by Professor
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Kaplan. 12 The concept of the metabolic syndrome has become well established as a highly atherogenic state in which insulin resistance, hyperglycemia, hypertension and lipid disorders cluster. 13 In this syndrome, visceral fat has been recognized to play a key role in the development of a variety of diseases including cardiovascular disease. Therefore, visceral fat syndrome closely resembles metabolic syndrome.
Factors inducing visceral fat accumulation
Sex hormones might be one of the factors determining body fat distribution. Visceral fat accumulation is more predominant in males than in females when compared among agematched individuals with similar body mass index. Earlier Fat topography Y Matsuzawa studies have shown a negative correlation between plasma levels of sex hormone-binding globulin and waist-hip ratio in females, indicating that an active form of testosterone is an important determinant of visceral adiposity in females. In contrast, in males, low testosterone levels were reported to relate to visceral adiposity. Aging is also an important factor in accumulation of visceral fat. A close linear correlation between age and visceral fat volume was shown in male subjects in a crosssectional study in 1557 obese individuals of varying ages. 14 Although this correlation was also present in female obese subjects, the slope was gentle in premenopausal individuals, but suddenly became steep in menopausal individuals, compared with that of males.
Among dietary factors, high sucrose intake is a candidate for promoting visceral fat accumulation. High sucrose loading has been known to cause the increase in mesenteric fat in both human and animal models. 15 Physical exercise has been suggested to prevent and reduce visceral fat accumulation. We analyzed fat distribution in Japanese Sumo wrestlers to investigate the effects of physical exercise on visceral adiposity. Sumo wrestlers eat a highenergy diet (7000-10 000 kcal) every day to gain weight, but at the same time they perform strenuous physical training daily. Although they show marked obesity and have markedly high waist circumference, the average ratio of visceral-to-subcutaneous fat is 0.25 in young Sumo wrestlers, which is comparable to subcutaneous obesity, and their glucose and lipid levels remain normal. A typical CT image of abdominal fat in Sumo wrestlers is shown in Figure 6 with metabolic parameters, showing very little intra-abdominal visceral fat with developed muscularity and increased subcutaneous fat with almost normal lipid and glucose metabolism. 16 The incidence of diabetes mellitus may increase in retired wrestlers who do not continue physical exercise, if they continue heavy caloric intake. Physical Fat topography Y Matsuzawa
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exercise is not only useful in preventing visceral fat accumulation but also in reducing visceral adiposity. It is noteworthy that subcutaneous adiposity is rather insensitive and not markedly altered in this condition. There may be genetic factors for visceral adiposity, as visceral obesities sometimes cluster in the same family. A non-conservative missense mutation in the b3-adrenergic receptor gene was suggested as a candidate for a genetic factor of visceral obesity. 17 Why does visceral fat play a key role in the development of multiple risks and cardiovascular disease? To answer this question, we have been investigating adipose tissue biology from two different approaches: (a) increased influx of free fatty acids (FFA) and glycerol from accumulated visceral fat to the liver, and (b) increased influx of FFA in the liver causing enhanced lipoprotein formation and secretion.
Increased influx of FFA and glycerol from accumulated visceral fat to the liver Visceral fat is characterized by enhanced lipolysis and augmented plasma FFA flux to the portal circulation, which is connected directly to the liver. Insulin resistance has been shown to be exacerbated by an increased supply of FFA to peripheral tissue and the liver. In vitro studies have shown that palmitate exposure caused dose-dependent reduction in cell-surface insulin receptor binding of isolated hepatocytes and, further, was associated with a proportionally diminished receptor-mediated internalization and with decreased intracellular and total receptor-mediated insulin degradation. This phenomenon may contribute to the reduced hepatic insulin extraction and peripheral hyperinsulinemia.
Increased FFA influx in the liver from accumulated visceral fat may contribute to the enhancement of lipoprotein secretion as well as lipoprotein formation. Recent studies indicate that microsomal triglyceride transfer protein plays a key role in the lipoprotein assembly of apolipoprotein B and lipids to form very-low-density lipoprotein in the liver. This process is considered to be a limiting factor for very-lowdensity lipoprotein secretion from the liver to plasma. Our group reported that FFA enhance mRNA expression of microsomal triglyceride transfer protein in the liver, which suggests that increased FFA influx to the liver from visceral fat may contribute increased very-low-density lipoprotein formation and secretion, and results in hyperlipidemia. 18 In contrast to the observation on FFA metabolism, the fate of glycerol, another metabolite of triglyceride lipolysis, has not been well investigated. 
We have been investigating biological and genetic characteristics of adipose tissue comparing subcutaneous fat with visceral fat as well as adipose tissue, or adipocytes with other mesenchymal cells to develop a comprehensive analysis of expressed genes in adipocytes. This research line, called the Body Map Project, compares the profile of expressed genes in adipocytes with the expressed genes in other mesenchymal cells. 19 In this research, we discovered an adipose tissuespecific water channel named aquaporin adipose or aquaporin 7. 20 Aquaporin adipose has been found to play an important role in membrane transport of glycerol. Aquaporin adipose mRNA is sensitive to feeding and fasting, in that fasting remarkably enhances the expression and feeding suppresses it. This regulation causes increased glycerol release from adipose tissue during fasting in order to supply glycerol from visceral fat to the liver to maintain hepatic glucose production. Insulin has a major role in the suppression of aquaporin mRNA at feeding. 21 However, mRNA expression of aquaporin adipose in visceral fat is enhanced in obese model animals, such as the db/db mouse, and the suppression by feeding does not occur, resulting in the increase of portal glycerol influx to the liver even at feeding stage ( Figure 7 ). From these results, it can be speculated that the physiological roles of aquaporin adipose in maintaining blood glucose levels, thus preventing hypoglycemia in the fasting stage by transporting glycerol, which is one of the products of lipolysis in visceral adipose tissue, to the liver. However, in visceral obesity, suppression system by insulin at feeding stage is impaired and excess glycerol influx to the liver may cause hyperglycemia, especially at post-prandial stage.
The concept of adipocytokines
In the Body Map Project, we analyzed the profile of expressed gene groups classified by their function or subcellular localization. As shown in Figure 8 , adipocytes abundantly express the genes encoding secretory proteins, most of which are important bioactive substances such as growth factors, cytokines and complements. 19 We named these adipose tissue-derived bioactive substances as adipocytokines (or adipokines). 22 Figure 9 shows representative adipocytokines that are related to pathophysiology and pathogenesis of metabolic syndrome. The secretion of these adipocytokines increases in obesity, especially with visceral fat accumulation. For example, plasma levels of plasminogen activator inhibitor 1 have been shown to correlate to visceral adiposity in humans. Animal experiments using ventromedial hypothalamus-lesioned rats revealed that mRNA levels of plasminogen activator inhibitor 1 in visceral fat, but not in subcutaneous fat, were enhanced in accordance with the development of obesity. 23 These data suggest that increased plasminogen activator inhibitor 1 levels caused by visceral fat accumulation may be one cause of vascular disease in the metabolic syndrome.
Discovery of adiponectin
In the Body Map Project, we identified several novel adipocytokines in addition to known bioactive substances. 
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Among them, adiponectin may be the most important, because this collagen-like protein has potent preventive properties against various common diseases. Adiponectin was expressed most abundantly among whole adipose tissue-expressed genes, and so we named the gene as 'adipose most abundant gene transcript-1' (apM-1). 24 The protein encoded by apM-1 was named 'adiponectin' because this collagen-like protein has a characteristic of matrix protein such as fibronectin. The adiponectin gene expresses only in adipose tissue. It has collagen repeat and C1q-like globular structure, and in plasma is present in a very unique structure with a polymerized bouquet-like form. Just after the discovery of adiponectin from human adipose tissue, we developed an assay system, which has shown that adiponectin plasma levels are highly significant for a variety of diseases. It should be noted that plasma levels of adiponectin are extremely high, amounting to 10-15 mg ml À1 in normal individuals, which far exceeds the typical levels of hormones or cytokines. Its plasma levels are strongly negatively correlated to visceral adiposity, but not to subcutaneous adiposity. 25 The mechanism by which plasma levels are reduced in individuals with visceral fat accumulation is not yet clarified. However, co-culture with visceral fat inhibits adiponectin secretion from subcutaneous adipocytes. This finding suggests that some inhibiting factors for adiponectin synthesis or secretion are secreted from visceral adipose tissue. Tumor necrosis factor-a (TNF-a) was reported to be a strong inhibitor of the adiponectin promoter activity. The negative correlation between visceral adiposity and adiponectin levels might be explained by the increased secretion of TNF-a from accumulated visceral fat as at least one mechanism. 26 Plasma adiponectin concentrations are lower in people who have type 2 diabetes mellitus than in body mass indexmatched controls. The plasma concentrations have been shown to correlate strongly with insulin sensitivity, which suggests that low plasma concentrations are related to insulin resistance. In a study of Pima Indians, individuals with high levels of adiponectin were less likely to develop type 2 diabetes than those with low concentrations. High adiponectin concentration was, therefore, a notable protective factor against development of type 2 diabetes. 27 Plasma levels of adiponectin are also decreased in hypertensive humans, irrespective of the presence of insulin resistance. Endothelium-dependent vasoreactivity is impaired in people with hypoadiponectinemia, which might be at least one mechanism of hypertension in visceral obesity.
Most importantly, plasma concentrations of adiponectin are lower in people with coronary heart disease than in controls, even when body mass index and age are matched. The Kaplan-Meier analysis in Italian individuals with renal insufficiency showed that those with high adiponectin concentrations were free from cardiovascular death for a longer time than other groups. 28 A case-control study performed in Japan showed that the group with the plasma levels o4 mg ml À1 has been shown to have an increased risk of coronary artery disease and multiple metabolic risk factors, which indicates that hypoadiponectinemia is a key factor in the metabolic syndrome. 29 A prospective study also confirmed that high adiponectin concentrations are associated with reduced risk of acute myocardial infarction in men. In addition to hypoadiponectinemia accompanied by visceral fat accumulation, genetic hypoadiponectinemia caused by a missense mutation has been reported, which also exhibits the clinical phenotype of metabolic syndrome 30 ( Figure 10 ). These clinical evidences show that hypoadiponectinemia is a strong risk factor for cardiovascular disease. 30 Adiponectin as a potent anti-inflammation adipocytokine As already mentioned, adiponectin has multiple functions for prevention of metabolic diseases and cardiovascular diseases. More recently, adiponectin was shown to prevent liver fibrosis and some kinds of cancer such as endometrial cancer, breast cancer, liver cancer and colon cancer. 31 In addition, recent evidences support its strong antiinflammatory function. We first reported that adiponectin suppresses the production of the potent pro-inflammatory cytokine TNF-a, in macrophages. 32 Treatment of cultured macrophages with adiponectin significantly inhibits their phagocytic activity and their lipopolysaccharide-induced production of TNF-a. Suppression of phagocytosis by adiponectin is mediated by one of the complement C1q receptors, C1qRp, because this function was completely abrogated by the addition of an anti-C1qRp monoclonal antibody. These observations suggest that adiponectin is an important negative regulator in immune and inflammation systems, indicating that it may be involved in controlling inflammatory responses through its inhibitory functions. 
In the process of development of atherosclerosis, macrophages play crucial roles in plaque formation but adiponectin attenuates cholesterol ester accumulation in them. The adiponectin-treated macrophages contained fewer lipid droplets stained by oil red O. Furthermore, adiponectin suppresses the expression of the class A macrophage scavenger receptor at both mRNA and protein levels by northern and immunoblot analyses, respectively, without affecting the expression of CD36, which was qualified by flow cytometry. 33 Adiponectin and TNF-a interactions are numerous. Adiponectin inhibited the TNF-a-induced mRNA expression of monocyte adhesion molecules without affecting the interaction between TNF-a and its receptors in human aortic endothelial cells. Adiponectin suppressed the TNF-a-induced inducible nuclear factor kappaB (IkB) a phosphorylation and subsequent nuclear factor-kB activation without affecting other TNF-a-mediated signals, including Jun N-terminal kinase, p38 kinase and Akt kinase. This inhibitory effect of adiponectin is accompanied by cAMP accumulation and is blocked by either adenylate cyclase inhibitor or protein kinase A inhibitor. 34 These observations suggest that adiponectin, which is naturally present at high levels in the blood stream, modulates the inflammatory response of both macrophages and endothelial cells through cross-talk between cAMP-protein kinase A and nuclear factor-kB signaling pathways. The anti-inflammatory function of adiponectin may prevent atherogenic cell phenomena, such as monocyte adhesion to endothelial cells, differentiation of monocytes to macrophages and, finally, foam cell formation. 35 Current studies have shown that adiponectin also induces various anti-inflammatory cytokines, such as interleukin-10 (IL-10) or IL-1 receptor antagonists, and IL-10 is a biomarker for risk in acute coronary syndrome. 36 Acute coronary syndrome determines the prognosis of cardiovascular disease, in which plaque vulnerability is the important determinant of plaque rupture. In the process of plaque rupture, matrix metalloproteinase secreted by macrophages is considered to increase plaque vulnerability.Tissue inhibitor of metalloproteinase (TIMP) appears to protect against plaque rapture by inhibition of matrix metalloproteinase activity. Adiponectin increases the expression of mRNA and protein production of TIMP in macrophages. 37 Before the induction of TIMP formation and secretion, adiponectin has been shown to induce IL-10 synthesis in macrophages, suggesting that adiponectin induces TIMP formation and secretion through the induction of IL-10 synthesis in an autocrine manner in macrophages, thus possibly inhibiting matrix metalloproteinase activity. 34 These functions may result in the prevention of acute coronary syndrome. As shown earlier, adiponectin is Fat topography Y Matsuzawa produced abundantly by adipose tissue in normal individuals and circulates in the blood stream. In addition, adiponectin strongly binds with subendothelial collagens such as collagen I, III, V, thus strengthening the sclerotic tissue plaque composition. 38 A possible mechanism of the prevention of atherosclerosis and acute coronary syndrome by adiponectin is shown in Figure 11 . Adiponectin, abundantly present in the blood stream, may enter injured vascular walls by binding to subendothelial collagens and protecting against a variety of atherosclerotic cell phenomena as mentioned above. Thus, adiponectin could be likened to firefighters who put out small fires (in vascular walls) before they become big fires.
Conclusion
Using CT scan for fat analysis revealed that intra-abdominal visceral fat accumulation has been shown to play crucial roles in the development of metabolic and cardiovascular diseases. Given these clinical findings, the functions of adipocytes have been intensively investigated in the past 10 years and have been shown to act as endocrine cells that secrete various bioactive substances and also as energystoring cells. Accumulation of visceral fat that links directly with the liver by portal circulation may induce hyperlipidemia and hyperglycemia through increased flux of FFA and glycerol to the liver. In addition, visceral fat accumulation may induce oversecretion of offensive adipocytokines, such as plasminogen activator inhibitor 1, TNF-a and herpin binding EGF-like growth factor (HB-EGF), and insufficient secretion of defensive adipocytokine, namely adiponectin ( Figure 12 ). The complex of these mechanisms may be present in the background of a variety of metabolic and cardiovascular disorders of visceral obesity.
